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HIV-ASSOCIATED NEUROMUSCULAR  
WEAKNESS SYNDROME IN BRAZIL
Report of the two first cases
José E. Vidal1,2, David Clifford3, Cláudio Meilman Ferreira4,  
Augusto C. Penalva de Oliveira1,4
ABSTRACT - We describe two Brazilian patients with HIV-associated neuromuscular weakness syndrome 
(HANWS), a unique clinical toxic syndrome that was recently reported in developed countries. Both pa-
tients were women, used stavudine and had hyperlactatemia, one of them with lactic acidosis. Eletrophys-
iological studies were consistent with axonal neuropathy. After discontinuation of antiretroviral therapy 
the patients had significant improvement in neurologic manifestations, and normalization of lactate lev-
els. To our knowledge, this is the first report of HANWS in developing countries. Growing use of antiretro-
viral therapy in this setting, particularly stavudine, make it likely that similar cases will be observed.
KEy WoRdS: neuromuscular diseases, peripheral neuropathies, antiretroviral agents, human immunode-
ficiency virus.
Síndrome da fraqueza neuromuscular associada ao HIV no Brasil: relato dos dois primeiros casos
RESUMo - os autores descrevem dois pacientes brasileiros com a síndrome da fraqueza neuromuscular 
associada ao HIV, uma síndrome tóxica, clínicamente particular, que foi recentemente relatada em paí-
ses desenvolvidos. Ambas pacientes eram do sexo feminino, usavam estavudina e apresentaram hiperlac-
tatemia, uma delas com acidose láctica. os exames electrofisiológicos foram consistentes com neuropatia 
axonal. As pacientes melhoraram significativamente das alterações neurológicas, assim como normaliza-
ram os níveis de lactato, após descontinuar o uso dos antiretrovirais. Até onde sabemos, este é o primei-
ro relato da síndrome de fraqueza neuromuscular associada ao HIV em países em desenvolvimento. Nes-
se contexto, o uso crescente de antiretrovirais, particularmente a estavudina, possibilitarão que casos si-
milares sejam observados. 
PAlAVRAS-CHAVE: doenças neuromusculares, neuropatia periférica, terapia antiretroviral, vírus da imu-
nodeficiência humana.
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The introduction of highly active antiretroviral 
therapy (HAART) has improved survival and quali-
ty of life of human immunodeficiency virus (HIV)-in-
fected patients in developed countries. Similar results 
were observed in Brazil, the first developing country 
with a policy of universal free access to HAART1. An-
tiretroviral therapy has also decreased the incidence 
of central nervous system (CNS) opportunistic diseas-
es2, which vary geographically3. However, toxic events 
secondary to use of HAART can be observed globally. 
Recently, Simpson et al., reported a heterogeneous 
syndrome termed the HIV-associated neuromuscular 
weakness syndrome (HANWS)4 ,which seems to be 
related to hyperlactatemia and stavudine and/or di-
danosine exposure4,5. While these drugs are routine-
ly part of therapy in developing nations, there has 
been no case reports of HANWS in resource-limit-
ed settings. 
Here, we present two Brazilian patients with 
HANWS. 
CASES
Case 1 – A 25 year-old HIV-infected woman with a previ-
ous history of cerebral toxoplasmosis, esophageal candidia-
sis, and a high blood pressure, presented to an out-patient 
clinic care with malaise, nausea and vomiting. She has used 
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stavudine, lamivudine and efavirenz for 11 months. one 
week later of the prior evaluation, she complained of ad-
ditional numbness in her feet. Two weeks after, stavudine 
was switched to tenofovir. At this point, her lactate levels 
were 4.4 mmol/l. one week later, she complained of weak-
ness in lower limbs, “pin and needles” sensation, and wors-
ening of numbness in her feet. This progressed over two 
weeks, despite the use of amytriptiline 25 mg/day, when 
she presented to our facility. At admission, she was mild-
ly dehydrated. Neurological examination disclosed severe 
weakness in lower limbs (grade 2) and she was unable to 
walk without help. decreased distal pinprick and vibration 
was noted, and deep tendon reflexes were lost at the knees 
and ankles. Plantar reflex were absent. She denied any uri-
nary or bowel dysfunction. Abnormal admission labs includ-
ed: Hb=11.9 mg/dl, AST=208 U/l, AlT=252 U/l, CPK=247 
U/l, GGT=178 U/l and K=3.0 mEq/l. A blood gas exchange 
showed pH 7.33, po2 93.2, pCo2 32.1, HCo3 13.5, BE –8, and 
Sat o2 96%. Serum lactate was 6.6 mmol/l. Cd4 cell count 
was 62/mm3 and HIV RNA levels <400 copies/ml. Nerve con-
duction studies of lower limbs revealed evidence of severe 
axonal sensory motor polyneuropathy, with signs of dener-
vation affecting distal and proximal segments. Brain and 
lumbar spinal cord computed tomography and cerebro-
spinal fluid were normal. HAART was withdrawn and she 
was treated with intravenous fluids and vitamin B complex 
supplement. over the following week, she had progres-
sive relief of the complaints with mild weakness (grade 4) 
and decreasing paresthesias, and lactate level falling to 4.1 
mmol/l. She was discharged with secondary prophylaxis for 
cerebral toxoplasmosis, amytriptiline 25 mg/day, and vita-
min B complex supplement. Two months after discharge, 
she had improved further having only mild weakness in 
lower limbs without parestesias. Muscular strength in the 
lower limbs was grade 4, she continued to have absent an-
kle reflexes, and diminished vibratory sensitivity. At this 
point, her lactate levels were 2.5 mmol/l, Cd4 cell count 
60/ mm3, and HIV RNA levels=179,000 copies/ml (5.25 log10). 
Tenofovir, efavirenz atazanavir and ritonavir were started. 
Three months after discharge, she was walking without 
difficulty, presented normal muscular strength in the low-
er limbs, and had normal lactate levels (1.5 mmol/l), Cd4 
cell count=123/mm3, and HIV RNA levels <400 copies/ml. 
Seven months after discharge, she was asymptomatic and 
maintained normal levels of lactate (1.2 mmol/l) along with 
Cd4 cell count=206/mm3 and HIV RNA levels <400 copies/
ml. Figure 1 shows the main laboratory results and their 
temporal association with the use of HAART. 
Case 2 – A 47 year-old HIV-infected women with a histo-
ry of previous intravenous drug use and pulmonary tuber-
culosis, presented to the emergency room unable to walk, 
and reporting numbness, tingling, and burning pain on her 
toes for two weeks. These symptoms rapidly ascended to 
her lower limbs, chest, and also involving upper limbs with-
in two days. She experienced progressive leg weakness, and 
was bed bound for the last four days due to extreme dif-
ficulty walking, but had no urinary dysfunction. Besides 
hyporexia and weight loss, she had no other complaints. 
She had been on stavudine, lamivudine and efavirenz three 
years ago. At admission, neurological examination revealed 
weakness of her right arm, and both legs (grade 3), with 
generalized areflexia. She had decreased light touch and 
pain sensation on her legs and trunk. Vibratory sensitivity 
was diminished in the legs. Plantar reflexes were absent. 
Cd4 cell count was 450/mm3, and HIV RNA levels=12,457 
copies/ml (4.0 log 10). Admission labs included: AST=64 U/
l, AlT=55 U/l, GGT=600 U/l, and dHl=645 U/l. A blood 
gas exchange evaluation showed pH 7.42, po2 97.1, pCo2 
28.5, HCo3 13.5, BE -4, Sat o2 98.5%. Serum lactate was 6.6 
Fig 1. Case 1: Laboratorial infor-
mation and correlation with highly 
active antiretroviral therpapy. d4T, 
stavudine; 3TC, lamivudine; TDF, te-
nofovir; EFV, efavirenz; ATV/r, ata-
zanavir/ritonavir; VL, viral load.
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mmol/l, and CPK was normal. Thyroid hormones, serum 
folic and vitamin B12 levels were normal. Magnetic reso-
nance imaging of the brain, thoracic and lumbar spine cord 
were normal. lumbar puncture was performed and results 
were normal. Nerve conduction studies revealed evidence 
of axonal sensory-motor polyradiculopathy, mild in upper 
limbs, and severe in lower limbs. HAART was withdrawn 
and she received vitamin B complex supplement and folic 
acid. Her symptoms improved slightly, and she reported few 
disabling paresthesias. After a transitory increase of venous 
lactate (up to 9.4 mmol/l), the levels declined progressive-
ly to 5.7 mmol/l. After three weeks of hospitalization, she 
was discharged home taking folic acid, vitamin B complex 
supplement, and amytriptiline 50 mg/day. No antiretroviral 
therapy was prescribed. Two weeks later, she was walking 
short distances with help, but reported persistent burning 
pain in legs, and continued to have leg weakness (grade 3), 
generalized areflexia, and diminished light touch and pain 
sensation in a stocking-glove pattern. At this point, her lac-
tate value was 2.5 mmol/l. Two months after discharge, the 
patient presented with leg strength grade 5, but continued 
to experience parethesias, partially controlled with amy-
triptyline 100 mg/day. At this point, her lactate value was 
2.2 mmol/l. Four months after discharge, HAART based on 
viral resistance genotyping was started using lamivudine, 
lopinavir / ritonavir and enfuvirtide (T20). one month later, 
her Cd4 cell count was 599/mm3 and HIV RNA levels=3,402 
(3.5 log10) with a lactate value of 1.4 mmol/l. Seven months 
after discharge, the patient presented with mild paresthe-
sias but lactate was 0.8 mmol/l. Figure 2 shows the main 
laboratorial information and its temporal association with 
the use of HAART.
The patients have formally given authorization for the 
publication of this report. 
DISCUSSION
To our knowledge, these patients represent the 
first reported Brazilian HIV-patients with HANWS. 
At present, the available data are insufficient to es-
timate the incidence of HANWS in this population. 
However, considering that there are about 170,000 
individuals in Brazil receiving antiretroviral therapy6, 
we would expect more similar cases. In recent years, 
a spectrum of metabolic and morphologic alterations 
has emerged among HIV-infected patients receiving 
HAART. Additionally, neurological syndromes, such 
as antiretroviral toxic neuropathy, have been clini-
cally well characterized7,8. The HANWS is a unique 
toxic syndrome, more recently reported, and to date 
incompletely characterized4.
The pathogenesis of neuromuscular syndrome in 
HIV-infected patients is probably multifactorial, and 
may result from a combination of mitochondrial and 
immunological mechanisms due to HIV and HAART9. 
In the initial description of HANWS, Simpson et al., 
reported 69 HIV-infected patients with HANWS, and 
approximately 75% of them with electrophysiological 
or pathological evidence of nerve or muscle disease 
had hyperlactatemia. Neurophysiological studies gen-
erally suggest axonal neuropathy, but may include 
some evidence of demyelination as well. A majority 
of patients presented axonal alterations, but if demy-
elinating findings are present, this might have ther-
apeutic implicantions, suggesting that intravenous 
immunoglobulin or plasmapheresis could be used10.
Fig 2. Case 2: Laboratorial infor-
mation and correlation with high-
ly active antiretroviral therapy. d4T, 
stavudine; 3TC, lamivudine; TDF, te-
nofovir; EFV, efavirenz; LPV/r, lopi-
navir/ritonavir; T20, enfuvirtide; 
VL, viral load.
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our two patients presented can be classified as 
definitive HANWS, using the criteria of Simpson et 
al.4 Both were females, and presented hyperlactate-
mia, however, only one presented lactic acidosis. As 
was observed in this report, the antiretroviral most 
often associated with HANWS was stavudine. Inter-
estingly, the immunological status was very differ-
ent in our patients (Cd4 cell count=62 / mm3 in Case 
1, and Cd4 cell count=450/mm3 in Case 2), suggest-
ing that risk for this condition may occur at variable 
stages. 
The treatment of HANWS is controversial, and 
important since this is potentially a fatal syndrome. 
our experience reinforces the recommendation that 
early interruption of HAART and clinical support is 
beneficial. 
Re-introduction of HAART after interruption due 
to mitochondrial toxicity is a challenge and no evi-
dence-based guidelines are available. options for 
patients with HANWS could include double-boost-
ed protease inhibitor (PI)11 ,combination of non-nu-
cleoside reverse transcriptase inhibitor (NNRTI) and 
boosted PI12, or a combination of a nucleotide ana-
logues, NNRTI, and a boosted PI (Case 1). other ther-
apeutic associations, such as PI with novel groups of 
antiretrovirals (p.e inhibitors of entry) can represent 
alternative options, especially in patients with high 
level of resistance (Case 2). Alternatively, avoiding 
stavudine or didanosine, the nucleosides with the 
highest association with mitochondrial toxicity, may 
be a satisfactory alternative in the long run. 
In developing countries, it is feared that wide-
spread use of stavudine, increased prevalence of 
HIV in women, and difficulty in monitoring thera-
py closely might lead to widespread HANWS with 
attendant morbidity and mortality. A further chal-
lenge is that the possibility of other etiologies in-
cluding nutricional deficits, and co-infections such as 
cytomegalovirus, tuberculosis, and syphilitic polyra-
diculomyelitis should be included in the differential 
diagnosis. These may be prominent issues in develop-
ing nations. optimal care will be include both early 
recognition of this syndrome with discontinuation 
of the nucleosides, supportive care, and appropriate 
exclusion of alternative treatable causes. 
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